Immediate outcome prognostic value of plasma factors in patients with acute ischemic stroke after intravenous thrombolytic treatment

In the present study, we explored multiple plasma factors to predict the outcomes of patients with AIS after IVT. Fifty AIS patients who received IVT with alteplase were recruited and divided into two groups according to their NIHSS scores. Serum from all subjects was collected to quantitatively ana...

Full description

Saved in:
Bibliographic Details
Published inBMC neurology Vol. 22; no. 1; pp. 1 - 9
Main Authors Lu, Huanhuan, Li, Siyi, Zhong, Xin, Huang, Shuxuan, Jiao, Xue, He, Guoyong, Jiang, Bingjian, Liu, Yuping, Gao, Zhili, Wei, Jinhong, Lin, Yushen, Chen, Zhi, Li, Yanhua
Format Journal Article
LanguageEnglish
Published London BioMed Central Ltd 20.09.2022
BioMed Central
BMC
Subjects
Online AccessGet full text

Cover

Loading…
Abstract In the present study, we explored multiple plasma factors to predict the outcomes of patients with AIS after IVT. Fifty AIS patients who received IVT with alteplase were recruited and divided into two groups according to their NIHSS scores. Serum from all subjects was collected to quantitatively analyze the levels of different plasma factors, IL-6, MMP-9, ADAMTS13, TNC, GSN and TRX, using Luminex assays or ELISA measurements. Compared with the levels assessed at the onset of AIS, the levels of MMP-9 ( P  < 0.001), ADAMTS13 ( P  < 0.001), and TRX ( P  < 0.001) significantly decreased after IVT. The level of IL-6 was significantly increased in the NIHSS > 5 group at admission ( P  < 0.001) compared to the NIHSS ≤ 5 group. AIS patients with a poor prognosis had lower levels of ADAMTS13 at 72 h post-IVT compared with patients with a good prognosis ( P  = 0.021). IL-6 also was notably higher in the poor outcome group ( P  = 0.012). After adjusting for confounders, ADAMTS13 at 72 h post-IVT was an independent protective factor for prognosis in AIS patients with an adjusted OR of 0.07 ( P  = 0.049), whereas IL-6 was an independent predictor of risk for AIS patients with an adjusted OR of 1.152 ( P  = 0.028). IVT decreased MMP-9, ADAMTS13, and TRX levels in the plasma of AIS patients. Patients with a NIHSS score of less than 5 exhibited lower IL-6 levels, indicating that increased levels of IL-6 correlated with AIS severity after IVT. Therefore, IL-6 and ADAMTS13 might be useful plasma markers to predict the prognosis in AIS patients at 90-days after IVT.
AbstractList In the present study, we explored multiple plasma factors to predict the outcomes of patients with AIS after IVT. Fifty AIS patients who received IVT with alteplase were recruited and divided into two groups according to their NIHSS scores. Serum from all subjects was collected to quantitatively analyze the levels of different plasma factors, IL-6, MMP-9, ADAMTS13, TNC, GSN and TRX, using Luminex assays or ELISA measurements. Compared with the levels assessed at the onset of AIS, the levels of MMP-9 (P < 0.001), ADAMTS13 (P < 0.001), and TRX (P < 0.001) significantly decreased after IVT. The level of IL-6 was significantly increased in the NIHSS > 5 group at admission (P < 0.001) compared to the NIHSS ≤ 5 group. AIS patients with a poor prognosis had lower levels of ADAMTS13 at 72 h post-IVT compared with patients with a good prognosis (P = 0.021). IL-6 also was notably higher in the poor outcome group (P = 0.012). After adjusting for confounders, ADAMTS13 at 72 h post-IVT was an independent protective factor for prognosis in AIS patients with an adjusted OR of 0.07 (P = 0.049), whereas IL-6 was an independent predictor of risk for AIS patients with an adjusted OR of 1.152 (P = 0.028). IVT decreased MMP-9, ADAMTS13, and TRX levels in the plasma of AIS patients. Patients with a NIHSS score of less than 5 exhibited lower IL-6 levels, indicating that increased levels of IL-6 correlated with AIS severity after IVT. Therefore, IL-6 and ADAMTS13 might be useful plasma markers to predict the prognosis in AIS patients at 90-days after IVT.In the present study, we explored multiple plasma factors to predict the outcomes of patients with AIS after IVT. Fifty AIS patients who received IVT with alteplase were recruited and divided into two groups according to their NIHSS scores. Serum from all subjects was collected to quantitatively analyze the levels of different plasma factors, IL-6, MMP-9, ADAMTS13, TNC, GSN and TRX, using Luminex assays or ELISA measurements. Compared with the levels assessed at the onset of AIS, the levels of MMP-9 (P < 0.001), ADAMTS13 (P < 0.001), and TRX (P < 0.001) significantly decreased after IVT. The level of IL-6 was significantly increased in the NIHSS > 5 group at admission (P < 0.001) compared to the NIHSS ≤ 5 group. AIS patients with a poor prognosis had lower levels of ADAMTS13 at 72 h post-IVT compared with patients with a good prognosis (P = 0.021). IL-6 also was notably higher in the poor outcome group (P = 0.012). After adjusting for confounders, ADAMTS13 at 72 h post-IVT was an independent protective factor for prognosis in AIS patients with an adjusted OR of 0.07 (P = 0.049), whereas IL-6 was an independent predictor of risk for AIS patients with an adjusted OR of 1.152 (P = 0.028). IVT decreased MMP-9, ADAMTS13, and TRX levels in the plasma of AIS patients. Patients with a NIHSS score of less than 5 exhibited lower IL-6 levels, indicating that increased levels of IL-6 correlated with AIS severity after IVT. Therefore, IL-6 and ADAMTS13 might be useful plasma markers to predict the prognosis in AIS patients at 90-days after IVT.
Abstract In the present study, we explored multiple plasma factors to predict the outcomes of patients with AIS after IVT. Fifty AIS patients who received IVT with alteplase were recruited and divided into two groups according to their NIHSS scores. Serum from all subjects was collected to quantitatively analyze the levels of different plasma factors, IL-6, MMP-9, ADAMTS13, TNC, GSN and TRX, using Luminex assays or ELISA measurements. Compared with the levels assessed at the onset of AIS, the levels of MMP-9 (P < 0.001), ADAMTS13 (P < 0.001), and TRX (P < 0.001) significantly decreased after IVT. The level of IL-6 was significantly increased in the NIHSS > 5 group at admission (P < 0.001) compared to the NIHSS ≤ 5 group. AIS patients with a poor prognosis had lower levels of ADAMTS13 at 72 h post-IVT compared with patients with a good prognosis (P = 0.021). IL-6 also was notably higher in the poor outcome group (P = 0.012). After adjusting for confounders, ADAMTS13 at 72 h post-IVT was an independent protective factor for prognosis in AIS patients with an adjusted OR of 0.07 (P = 0.049), whereas IL-6 was an independent predictor of risk for AIS patients with an adjusted OR of 1.152 (P = 0.028). IVT decreased MMP-9, ADAMTS13, and TRX levels in the plasma of AIS patients. Patients with a NIHSS score of less than 5 exhibited lower IL-6 levels, indicating that increased levels of IL-6 correlated with AIS severity after IVT. Therefore, IL-6 and ADAMTS13 might be useful plasma markers to predict the prognosis in AIS patients at 90-days after IVT.
In the present study, we explored multiple plasma factors to predict the outcomes of patients with AIS after IVT. Fifty AIS patients who received IVT with alteplase were recruited and divided into two groups according to their NIHSS scores. Serum from all subjects was collected to quantitatively analyze the levels of different plasma factors, IL-6, MMP-9, ADAMTS13, TNC, GSN and TRX, using Luminex assays or ELISA measurements. Compared with the levels assessed at the onset of AIS, the levels of MMP-9 (P < 0.001), ADAMTS13 (P < 0.001), and TRX (P < 0.001) significantly decreased after IVT. The level of IL-6 was significantly increased in the NIHSS > 5 group at admission (P < 0.001) compared to the NIHSS ≤ 5 group. AIS patients with a poor prognosis had lower levels of ADAMTS13 at 72 h post-IVT compared with patients with a good prognosis (P = 0.021). IL-6 also was notably higher in the poor outcome group (P = 0.012). After adjusting for confounders, ADAMTS13 at 72 h post-IVT was an independent protective factor for prognosis in AIS patients with an adjusted OR of 0.07 (P = 0.049), whereas IL-6 was an independent predictor of risk for AIS patients with an adjusted OR of 1.152 (P = 0.028). IVT decreased MMP-9, ADAMTS13, and TRX levels in the plasma of AIS patients. Patients with a NIHSS score of less than 5 exhibited lower IL-6 levels, indicating that increased levels of IL-6 correlated with AIS severity after IVT. Therefore, IL-6 and ADAMTS13 might be useful plasma markers to predict the prognosis in AIS patients at 90-days after IVT.
In the present study, we explored multiple plasma factors to predict the outcomes of patients with AIS after IVT. Fifty AIS patients who received IVT with alteplase were recruited and divided into two groups according to their NIHSS scores. Serum from all subjects was collected to quantitatively analyze the levels of different plasma factors, IL-6, MMP-9, ADAMTS13, TNC, GSN and TRX, using Luminex assays or ELISA measurements. Compared with the levels assessed at the onset of AIS, the levels of MMP-9 ( P  < 0.001), ADAMTS13 ( P  < 0.001), and TRX ( P  < 0.001) significantly decreased after IVT. The level of IL-6 was significantly increased in the NIHSS > 5 group at admission ( P  < 0.001) compared to the NIHSS ≤ 5 group. AIS patients with a poor prognosis had lower levels of ADAMTS13 at 72 h post-IVT compared with patients with a good prognosis ( P  = 0.021). IL-6 also was notably higher in the poor outcome group ( P  = 0.012). After adjusting for confounders, ADAMTS13 at 72 h post-IVT was an independent protective factor for prognosis in AIS patients with an adjusted OR of 0.07 ( P  = 0.049), whereas IL-6 was an independent predictor of risk for AIS patients with an adjusted OR of 1.152 ( P  = 0.028). IVT decreased MMP-9, ADAMTS13, and TRX levels in the plasma of AIS patients. Patients with a NIHSS score of less than 5 exhibited lower IL-6 levels, indicating that increased levels of IL-6 correlated with AIS severity after IVT. Therefore, IL-6 and ADAMTS13 might be useful plasma markers to predict the prognosis in AIS patients at 90-days after IVT.
In the present study, we explored multiple plasma factors to predict the outcomes of patients with AIS after IVT. Fifty AIS patients who received IVT with alteplase were recruited and divided into two groups according to their NIHSS scores. Serum from all subjects was collected to quantitatively analyze the levels of different plasma factors, IL-6, MMP-9, ADAMTS13, TNC, GSN and TRX, using Luminex assays or ELISA measurements. Compared with the levels assessed at the onset of AIS, the levels of MMP-9 (P < 0.001), ADAMTS13 (P < 0.001), and TRX (P < 0.001) significantly decreased after IVT. The level of IL-6 was significantly increased in the NIHSS > 5 group at admission (P < 0.001) compared to the NIHSS [less than or equai to] 5 group. AIS patients with a poor prognosis had lower levels of ADAMTS13 at 72 h post-IVT compared with patients with a good prognosis (P = 0.021). IL-6 also was notably higher in the poor outcome group (P = 0.012). After adjusting for confounders, ADAMTS13 at 72 h post-IVT was an independent protective factor for prognosis in AIS patients with an adjusted OR of 0.07 (P = 0.049), whereas IL-6 was an independent predictor of risk for AIS patients with an adjusted OR of 1.152 (P = 0.028). IVT decreased MMP-9, ADAMTS13, and TRX levels in the plasma of AIS patients. Patients with a NIHSS score of less than 5 exhibited lower IL-6 levels, indicating that increased levels of IL-6 correlated with AIS severity after IVT. Therefore, IL-6 and ADAMTS13 might be useful plasma markers to predict the prognosis in AIS patients at 90-days after IVT.
In the present study, we explored multiple plasma factors to predict the outcomes of patients with AIS after IVT. Fifty AIS patients who received IVT with alteplase were recruited and divided into two groups according to their NIHSS scores. Serum from all subjects was collected to quantitatively analyze the levels of different plasma factors, IL-6, MMP-9, ADAMTS13, TNC, GSN and TRX, using Luminex assays or ELISA measurements. Compared with the levels assessed at the onset of AIS, the levels of MMP-9 (P < 0.001), ADAMTS13 (P < 0.001), and TRX (P < 0.001) significantly decreased after IVT. The level of IL-6 was significantly increased in the NIHSS > 5 group at admission (P < 0.001) compared to the NIHSS [less than or equai to] 5 group. AIS patients with a poor prognosis had lower levels of ADAMTS13 at 72 h post-IVT compared with patients with a good prognosis (P = 0.021). IL-6 also was notably higher in the poor outcome group (P = 0.012). After adjusting for confounders, ADAMTS13 at 72 h post-IVT was an independent protective factor for prognosis in AIS patients with an adjusted OR of 0.07 (P = 0.049), whereas IL-6 was an independent predictor of risk for AIS patients with an adjusted OR of 1.152 (P = 0.028). IVT decreased MMP-9, ADAMTS13, and TRX levels in the plasma of AIS patients. Patients with a NIHSS score of less than 5 exhibited lower IL-6 levels, indicating that increased levels of IL-6 correlated with AIS severity after IVT. Therefore, IL-6 and ADAMTS13 might be useful plasma markers to predict the prognosis in AIS patients at 90-days after IVT. Keywords: Acute ischemic stroke, Intravenous thrombolysis, Plasma factors, NIHSS score, Prognosis
ArticleNumber 359
Audience Academic
Author Zhong, Xin
Jiao, Xue
Jiang, Bingjian
Gao, Zhili
Li, Siyi
Liu, Yuping
Chen, Zhi
Lu, Huanhuan
Lin, Yushen
He, Guoyong
Wei, Jinhong
Huang, Shuxuan
Li, Yanhua
Author_xml – sequence: 1
  givenname: Huanhuan
  surname: Lu
  fullname: Lu, Huanhuan
– sequence: 2
  givenname: Siyi
  surname: Li
  fullname: Li, Siyi
– sequence: 3
  givenname: Xin
  surname: Zhong
  fullname: Zhong, Xin
– sequence: 4
  givenname: Shuxuan
  surname: Huang
  fullname: Huang, Shuxuan
– sequence: 5
  givenname: Xue
  surname: Jiao
  fullname: Jiao, Xue
– sequence: 6
  givenname: Guoyong
  surname: He
  fullname: He, Guoyong
– sequence: 7
  givenname: Bingjian
  surname: Jiang
  fullname: Jiang, Bingjian
– sequence: 8
  givenname: Yuping
  surname: Liu
  fullname: Liu, Yuping
– sequence: 9
  givenname: Zhili
  surname: Gao
  fullname: Gao, Zhili
– sequence: 10
  givenname: Jinhong
  surname: Wei
  fullname: Wei, Jinhong
– sequence: 11
  givenname: Yushen
  surname: Lin
  fullname: Lin, Yushen
– sequence: 12
  givenname: Zhi
  surname: Chen
  fullname: Chen, Zhi
– sequence: 13
  givenname: Yanhua
  surname: Li
  fullname: Li, Yanhua
BookMark eNp9ks1u1DAUhSNUJNrCC7CyxIZNiu04trNBqip-RqrEBtaW49zMeEjiYDuDuu-Dc9MpgqkQiqJE9jlfco_PRXE2hQmK4jWjV4xp-S4xrnVVUs7x1o0u5bPinAnFSl4pdfbX-4viIqU9pUxpwc6L-804QudtBhKW7MIIZI5hO4WUvSMHOyy40ZN5sGm0pLcuh5iIn8hss4cpJ_LT5x2xbkGCT24HI_pSjuE7ENtniCjO0R5gCksieRfD2IbhbqXnCDaPCHlZPO_tkODV4_Oy-Pbxw9ebz-Xtl0-bm-vb0tWC5pJrwYFJxaBytJcAjZNQs5ratrGi0rrrtGaaVq1zWtra1a7ljZR1p3pZU11dFpsjtwt2b-boRxvvTLDePCyEuDU24p8NYNquEcBaTRshBFe8lbxyGqhVXMm-A2S9P7LmpcUEHaxTDifQ053J78w2HEwjtGJcIuDtIyCGHwukbEbMD4bBToBRGa6YrHktqgalb55I92GJE0aFKi6pbqRmf1RbiwP4qQ_4XbdCzbXCkghO2cq6-ocKr249OWxV73H9xKCPBhdDShF643zGww_rWH4wjJq1guZYQYMVNA8VNOuI_In1dzz_Mf0CYGPiqQ
CitedBy_id crossref_primary_10_1186_s41983_024_00829_5
crossref_primary_10_4103_jcsr_jcsr_251_22
crossref_primary_10_3390_biom15040470
Cites_doi 10.31083/j.jin2003078
10.1097/CRD.0000000000000021
10.1182/bloodadvances.2019000979
10.1016/j.neuroscience.2020.10.034
10.14336/AD.2018.0820
10.1136/neurintsurg-2021-018589
10.1007/s11011-019-00403-6
10.1038/jcbfm.2012.88
10.1007/s00018-019-03175-5
10.1111/ane.13487
10.1212/WNL.0000000000005162
10.1016/j.jstrokecerebrovasdis.2009.10.008
10.3389/fneur.2021.744909
10.1016/j.jstrokecerebrovasdis.2016.09.043
10.12659/MSM.908441
10.1212/WNL.0000000000011268
10.1186/1742-2094-5-45
10.1111/ene.14199
10.1038/nri1664
10.1186/1471-2377-11-41
10.1177/0271678X211056392
10.1371/journal.pmed.1000145
10.1186/1471-2377-4-2
10.1089/ars.2012.4757
10.1016/S1474-4422(21)00252-0
10.1016/S1474-4422(21)00237-4
10.1186/s12883-019-1375-6
ContentType Journal Article
Copyright COPYRIGHT 2022 BioMed Central Ltd.
2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2022. The Author(s).
The Author(s) 2022
Copyright_xml – notice: COPYRIGHT 2022 BioMed Central Ltd.
– notice: 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2022. The Author(s).
– notice: The Author(s) 2022
DBID AAYXX
CITATION
3V.
7TK
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s12883-022-02898-6
DatabaseName CrossRef
ProQuest Central (Corporate)
Neurosciences Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni)
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

Publicly Available Content Database
CrossRef



Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1471-2377
EndPage 9
ExternalDocumentID oai_doaj_org_article_bd94e1b809444272b623c8e0a7276fde
PMC9487126
A718642019
10_1186_s12883_022_02898_6
GeographicLocations Taiwan
China
GeographicLocations_xml – name: Taiwan
– name: China
GrantInformation_xml – fundername: ;
  grantid: 82160239
– fundername: ;
  grantid: 2020GXNSFAA297002
– fundername: ;
  grantid: S2019089
GroupedDBID ---
0R~
23N
2WC
53G
5VS
6J9
6PF
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
AAYXX
ABDBF
ABIVO
ABUWG
ACGFO
ACGFS
ACIHN
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
EMB
EMK
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IGS
IHR
INH
INR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
TUS
UKHRP
W2D
WOQ
WOW
XSB
PMFND
3V.
7TK
7XB
8FK
AZQEC
DWQXO
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c540t-2842e1671e3c0f6ee9c6e5150ab9a4388dd881803bcc86a5c5cb29665d7f65083
IEDL.DBID M48
ISSN 1471-2377
IngestDate Wed Aug 27 01:30:46 EDT 2025
Thu Aug 21 18:39:53 EDT 2025
Fri Jul 11 07:23:03 EDT 2025
Fri Jul 25 21:41:25 EDT 2025
Tue Jun 17 21:01:15 EDT 2025
Tue Jun 10 20:41:23 EDT 2025
Tue Jul 01 00:37:38 EDT 2025
Thu Apr 24 22:56:26 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c540t-2842e1671e3c0f6ee9c6e5150ab9a4388dd881803bcc86a5c5cb29665d7f65083
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://www.proquest.com/docview/2726089681?pq-origsite=%requestingapplication%
PQID 2726089681
PQPubID 44772
PageCount 9
ParticipantIDs doaj_primary_oai_doaj_org_article_bd94e1b809444272b623c8e0a7276fde
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9487126
proquest_miscellaneous_2716525439
proquest_journals_2726089681
gale_infotracmisc_A718642019
gale_infotracacademiconefile_A718642019
crossref_citationtrail_10_1186_s12883_022_02898_6
crossref_primary_10_1186_s12883_022_02898_6
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-09-20
PublicationDateYYYYMMDD 2022-09-20
PublicationDate_xml – month: 09
  year: 2022
  text: 2022-09-20
  day: 20
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
PublicationTitle BMC neurology
PublicationYear 2022
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References H Tang (2898_CR9) 2021; 12
CJ Smith (2898_CR14) 2004; 4
B Chelluboina (2898_CR27) 2022; 42
J Montaner (2898_CR7) 2019; 76
M Ramos-Fernandez (2898_CR22) 2011; 20
MK McCoy (2898_CR13) 2008; 5
V Prochazka (2898_CR25) 2018; 24
A Jurcau (2898_CR3) 2021; 20
W Whiteley (2898_CR11) 2009; 6
G Tsivgoulis (2898_CR8) 2020; 27
SM Allan (2898_CR12) 2005; 5
GBD 2019 Stroke collaborators (2898_CR1) 2021; 20
L Mechtouff (2898_CR5) 2021; 96
G Turc (2898_CR2) 2022; 14
MM Abdelnaseer (2898_CR21) 2017; 26
A Bustamante (2898_CR24) 2018; 90
DF Mahmood (2898_CR26) 2013; 19
E Reiche (2898_CR17) 2019; 34
F Purroy (2898_CR16) 2021; 144
A Taylor (2898_CR23) 2020; 4
DS Reich (2898_CR4) 2021; 20
J Hartman (2898_CR20) 2014; 22
KL Lambertsen (2898_CR10) 2012; 32
A Mengel (2898_CR19) 2019; 19
X Li (2898_CR18) 2019; 10
AS Douglas (2898_CR6) 2021; 453
M Beridze (2898_CR15) 2011; 11
References_xml – volume: 20
  start-page: 727
  year: 2021
  ident: 2898_CR3
  publication-title: J Integr Neurosci
  doi: 10.31083/j.jin2003078
– volume: 22
  start-page: 147
  year: 2014
  ident: 2898_CR20
  publication-title: Cardiol Rev
  doi: 10.1097/CRD.0000000000000021
– volume: 4
  start-page: 398
  year: 2020
  ident: 2898_CR23
  publication-title: Blood Adv
  doi: 10.1182/bloodadvances.2019000979
– volume: 453
  start-page: 256
  year: 2021
  ident: 2898_CR6
  publication-title: Neurosci
  doi: 10.1016/j.neuroscience.2020.10.034
– volume: 10
  start-page: 544
  year: 2019
  ident: 2898_CR18
  publication-title: Aging Dis
  doi: 10.14336/AD.2018.0820
– volume: 14
  start-page: 209
  year: 2022
  ident: 2898_CR2
  publication-title: J Neurointerv Surg
  doi: 10.1136/neurintsurg-2021-018589
– volume: 34
  start-page: 789
  year: 2019
  ident: 2898_CR17
  publication-title: Metab Brain Dis
  doi: 10.1007/s11011-019-00403-6
– volume: 32
  start-page: 1677
  year: 2012
  ident: 2898_CR10
  publication-title: J Cereb Blood Flow Metab
  doi: 10.1038/jcbfm.2012.88
– volume: 76
  start-page: 3117
  year: 2019
  ident: 2898_CR7
  publication-title: Cell Mol Life Sci
  doi: 10.1007/s00018-019-03175-5
– volume: 144
  start-page: 517
  year: 2021
  ident: 2898_CR16
  publication-title: Acta Neurol Scand
  doi: 10.1111/ane.13487
– volume: 90
  start-page: e995
  year: 2018
  ident: 2898_CR24
  publication-title: Neurol
  doi: 10.1212/WNL.0000000000005162
– volume: 20
  start-page: 47
  year: 2011
  ident: 2898_CR22
  publication-title: J Stroke Cerebrovasc Dis
  doi: 10.1016/j.jstrokecerebrovasdis.2009.10.008
– volume: 12
  start-page: 744909
  year: 2021
  ident: 2898_CR9
  publication-title: Front Neurol
  doi: 10.3389/fneur.2021.744909
– volume: 26
  start-page: 733
  year: 2017
  ident: 2898_CR21
  publication-title: J Stroke Cerebrovasc Dis
  doi: 10.1016/j.jstrokecerebrovasdis.2016.09.043
– volume: 24
  start-page: 3929
  year: 2018
  ident: 2898_CR25
  publication-title: Med Sci Monit
  doi: 10.12659/MSM.908441
– volume: 96
  start-page: e752
  year: 2021
  ident: 2898_CR5
  publication-title: Neurol
  doi: 10.1212/WNL.0000000000011268
– volume: 5
  start-page: 45
  year: 2008
  ident: 2898_CR13
  publication-title: J Neuroinflammation
  doi: 10.1186/1742-2094-5-45
– volume: 27
  start-page: 1039
  year: 2020
  ident: 2898_CR8
  publication-title: Eur J Neurol
  doi: 10.1111/ene.14199
– volume: 5
  start-page: 629
  year: 2005
  ident: 2898_CR12
  publication-title: Nat Rev Immunol
  doi: 10.1038/nri1664
– volume: 11
  start-page: 41
  year: 2011
  ident: 2898_CR15
  publication-title: BMC Neurol
  doi: 10.1186/1471-2377-11-41
– volume: 42
  start-page: 253
  year: 2022
  ident: 2898_CR27
  publication-title: J Cereb Blood Flow Metab
  doi: 10.1177/0271678X211056392
– volume: 6
  start-page: e1000145
  year: 2009
  ident: 2898_CR11
  publication-title: PLOS MED
  doi: 10.1371/journal.pmed.1000145
– volume: 4
  start-page: 2
  year: 2004
  ident: 2898_CR14
  publication-title: BMC Neurol
  doi: 10.1186/1471-2377-4-2
– volume: 19
  start-page: 1266
  year: 2013
  ident: 2898_CR26
  publication-title: Antioxid Redox Signal
  doi: 10.1089/ars.2012.4757
– volume: 20
  start-page: 795
  year: 2021
  ident: 2898_CR1
  publication-title: Lancet Neurol
  doi: 10.1016/S1474-4422(21)00252-0
– volume: 20
  start-page: 729
  year: 2021
  ident: 2898_CR4
  publication-title: Lancet Neurol
  doi: 10.1016/S1474-4422(21)00237-4
– volume: 19
  start-page: 148
  year: 2019
  ident: 2898_CR19
  publication-title: BMC Neurol
  doi: 10.1186/s12883-019-1375-6
SSID ssj0017841
Score 2.3224258
Snippet In the present study, we explored multiple plasma factors to predict the outcomes of patients with AIS after IVT. Fifty AIS patients who received IVT with...
Abstract In the present study, we explored multiple plasma factors to predict the outcomes of patients with AIS after IVT. Fifty AIS patients who received IVT...
SourceID doaj
pubmedcentral
proquest
gale
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage 1
SubjectTerms Acute ischemic stroke
Analysis
Biomarkers
Blood pressure
Cardiac arrhythmia
Cardiovascular disease
Diabetes
Enzyme-linked immunosorbent assay
Gelatinase B
Hemorrhage
Hyperlipidemia
Hypertension
Interleukin 6
Intravenous administration
Intravenous therapy
Intravenous thrombolysis
Ischemia
NIHSS score
Normal distribution
Patient outcomes
Patients
Plasma
Plasma cells
Plasma factors
Prevention
Prognosis
Risk factors
Statistical analysis
Stroke
Stroke (Disease)
Thrombolysis
Thrombolytic drugs
Tumors
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Nb9UwDI_QDogL4lMUBgoSEgdUrUnbNDluE9NAGicm7RblwxVP7LXTXt-BO384dpr3tIIEF66NkzaxE9uN_TNj7xrQMnbal73pTdkEdFC0in0pa-MiOGGioUThiy_q_LL5fNVe3Sn1RTFhMzzwvHBHPpoGhNfohjSN7KRHfR00VA4Vr-oj0OmLOm_nTOX7A7pN26XIaHW0EVRUt6TIdbpZ06VaqKGE1v_nmfx7nOQdxXP2iD3MFiM_nr_0MbsHwxN2_yLfiT9lPz-tU_rHBHzcTihAwCnoahgJgZkTmDc29PwGzeS147m-Dl8NPEOqbjj9i-UubHGEFTq7FC7PN9Pt-B14KiGOxBNVKSI0V051FdZ-vP5Bo-_D1J-xy7OPX0_Py1xboQxoo00laiUJQnUC6lD1CsAEBWjbVM4b19Rax6gpDbz2IWjl2tAGL9E1amPXk1FXP2cHwzjAC8Y1jqNFMEpTQoNXnqwkU7kQ2t7FVhZM7Jbahgw8TvUvrm1yQLSyM3sssscm9lhVsA_7Pjcz7MZfqU-Ig3tKgsxOD1CQbBYk-y9BKth74r-ljY2fF1zOT8BJEkSWPUYtjs4amsQFO1xQ4oYMy-adBNl8IGwsvlBVGtdIFOztvpl6UpDbAMhApBGqJXACHKJbSN5iZsuWYfUtgYIb9DyFVC__x1K8Yg9k2isGD9FDdjDdbuE12l6Tf5O22S_eSi3h
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELZokVAvCAqogYJcqRIHZHWdh2OfUEFUBak9UWlvll-BVbvJsskeuPPDmfF6AwGp17XjrDMz9jf2zDeEnJZB5r6WljWqUax04KBI4RuWF8r4YLjyChOFr67F5U35ZV7N04Fbn8Iqd2tiXKh95_CM_CyvAXlLJSR_v_rBsGoU3q6mEhp75CFSl6FW1_PR4eJ4p7ZLlJHirOdYWpdh_Drer0kmJptR5Oz_f2X-N1ryr-3n4gl5nHAjPd8K-il5ENpD8ugq3Yw_I78-L2MSyBBotxlgSoFi6FXbIQ8zRUpvaGjoCsDy0tBUZYcuWpqIVXuKJ7LUuA2MsACXF4PmaT-su9tAYyFx6DxgrSLkdKVYXWFpu7ufOPoYrP6c3Fx8-vrxkqUKC8wBUhsY7E154KLmoXCzRoSgnAiAcGbGKlMWUnovMRm8sM5JYSpXOZuDg1T5ukFoV7wg-23XhiNCJYwjuQMBYVqDFRaxkpoZ56rG-CrPCN99au0S_ThWwbjT0Q2RQm_Fo0E8OopHi4y8G59Zbck37u39ASU49kTi7PhDt_6mkx1q61UZuJXg1ZYl6JQF-OdkmBnAcaLxISNvUf4azRv-njMpSwEmiURZ-hz2cnDZABhn5HjSE8zSTZt3GqTTstDrP0qckZOxGZ_EULc2gAChDxcVUhTAEPVE8yYzm7a0i--RGlyB_8lz8fL-l78iB3m0AgWL5DHZH9ab8Bqw1WDfRAP6Db6HJbM
  priority: 102
  providerName: ProQuest
Title Immediate outcome prognostic value of plasma factors in patients with acute ischemic stroke after intravenous thrombolytic treatment
URI https://www.proquest.com/docview/2726089681
https://www.proquest.com/docview/2716525439
https://pubmed.ncbi.nlm.nih.gov/PMC9487126
https://doaj.org/article/bd94e1b809444272b623c8e0a7276fde
Volume 22
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3di9QwEA_3AeKL-InVc4kg-CDVph_5eBC5lTtOYQ85XFh8CUma6uJue-52wXv3D3cm265WD8GXPjTptM3MdGaamd8Q8iz3Mi2FtHGlKhXnDgIUycsqTjNlSm-YKhUWCk_O-dk0fz8rZnukb3fULeD62tAO-0lNV4uX379dvQGFfx0UXvJXa4Ytc2PMS8d9MxnzfXIIlklgR4NJ_mtXAffYQrWRYPAwQvRFNNfSGBiqgOf_91f7z0zK30zT6W1yq_Mp6fFWCO6QPV_fJTcm3a75PfLj3TIUiLSeNpsWRMxTTMuqG8Ropgj3DQMVvQRHemlo14GHzmvaga6uKf6tpcZtgMIc1gwT6um6XTVfPQ1NxmFyi32MEO-VYueFpW0WV0h9l8h-n0xPTz6-PYu77guxAy-ujcFupZ5xwXzmkop7rxz34P0kxiqTZ1KWpcRC8cw6J7kpXOFsCsFTUYoK3b7sATmom9o_JFQCHcmc4hJLHiy36EepxDhXVKYs0oiwfqm166DJsUPGQocQRXK9ZY8G9ujAHs0j8mJ3zeUWmOOfs8fIwd1MBNUOJ5rVZ93pqLalyj2zEiLePE9FasE1dNInBnw8XpU-Is-R_xqFER7Pma6CAV4SQbT0Mdh5COfAaY7I0WAmqKwbDvcSpHuJ13BDnkhYIxaRp7thvBLT4GoPDIQ5jBcIXwAkxEDyBm82HKnnXwJsuILYlKX80X8t3GNyMw1KoeB7ekQO2tXGPwE3rLUjsi9mYkQOxyfnHy5G4WfGKOgbHC_Gn34Cq40zFA
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKkYBLxVMNLWAkEAcUNc7DsQ8IlUe1S7s9tdLejF-BFd1k2c0K9c7v4Tcyk00CAam3XuOJk3jGM9_E8yDkRepF7HJhwkIWMkwtOCiCuyKME6md10w6iYnCk1M-Ok8_TbPpFvnV5cJgWGWnExtF7SqL_8gP4hyQt5BcsLeL7yF2jcLT1a6FxkYsjv3lD3DZVm_GH4C_L-P46OPZ-1HYdhUILaCTOgR9HHvGc-YTGxXce2m5B6seaSN1mgjhnMAE6MRYK7jObGZNDE5B5vIC4UwC894gN8HwRujs5dPewWN4htcl5gh-sGLYyjfEeHk8zxMhHxi_pkfA_5bg3-jMv8zd0V2y0-JUergRrHtky5f3ya1JexL_gPwcz5ukk9rTal3DEnqKoV5lhXWfKZYQh4GCLgCczzVtu_rQWUnbQq4rin-AqbZrmGEGLjYG6dNVvay-edo0LgfiGnsjYQ1Zit0c5qa6uMTZ--D4h-T8Wtb-Edkuq9LvEipgHsEsCASmURhuEJvJSFubFdplcUBYt9TKtuXOsevGhWrcHsHVhj0K2KMa9igekNf9PYtNsY8rqd8hB3tKLNTdXKiWX1S775VxMvXMCPCi0xRk2ADctMJHGnAjL5wPyCvkv0J1Aq9ndZsVAR-JhbnUIWAHcBEBiAdkf0AJasAOhzsJUq0aWqk_myYgz_thvBND60oPDAQaxjMsiQBT5APJG3zZcKScfW1KkUvwd1nMH1_98Gfk9uhscqJOxqfHe-RO3OwICQp6n2zXy7V_AriuNk-bzUTJ5-vevb8BiMphsg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Immediate+outcome+prognostic+value+of+plasma+factors+in+patients+with+acute+ischemic+stroke+after+intravenous+thrombolytic+treatment&rft.jtitle=BMC+neurology&rft.au=Lu%2C+Huanhuan&rft.au=Li%2C+Siyi&rft.au=Zhong%2C+Xin&rft.au=Huang%2C+Shuxuan&rft.date=2022-09-20&rft.issn=1471-2377&rft.eissn=1471-2377&rft.volume=22&rft.issue=1&rft_id=info:doi/10.1186%2Fs12883-022-02898-6&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s12883_022_02898_6
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2377&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2377&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2377&client=summon